PROPANC BIOPHARMA, INC. (PPCB) Operating income 2017–2026
PROPANC BIOPHARMA, INC. (PPCB) annual operating income history from SEC filings — each fiscal year as reported.
-$18.2MFY2026 · since FY2017: -$5.7M → -$18.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$18.2M | +68.3% |
| FY2025 | -$57.3M | -3628.9% |
| FY2024 | -$1.5M | +13.5% |
| FY2023 | -$1.8M | +10.8% |
| FY2022 | -$2.0M | -9.9% |
| FY2021 | -$1.8M | +48.1% |
| FY2020 | -$3.5M | -33.6% |
| FY2019 | -$2.6M | +34.0% |
| FY2018 | -$4.0M | +31.0% |
| FY2017 | -$5.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PPCB financial trends
PPCB RevenuePPCB Net incomePPCB Net marginPPCB Gross profitPPCB Gross marginPPCB Operating marginPPCB Operating cash flowPPCB Free cash flowPPCB Capital expendituresPPCB Return on equityPPCB Stock buybacksPPCB Dividends paidPPCB Total assetsPPCB Total liabilitiesPPCB Shareholders’ equityPPCB overview →